Lepodisiran clinical trials
Also written LY3819469.
Includes 1 study of Lepodisiran sodium.
How each study uses lepodisiran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the lepodisiran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test lepodisiran.
- Mar 2027A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Phase 1 · Eli Lilly and Company
Studies
Open first, then newest update. How each study uses lepodisiran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Not yet recruitingPhase 1Eli Lilly and CompanyNCT07914738Written as LY3819469
- A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High RiskRecruitingPhase 3Eli Lilly and CompanyNCT07613294On coronary plaque in high Lp(a)Written as Lepodisiran
- A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)Active, not recruitingPhase 3Eli Lilly and CompanyNCT06292013On major cardiovascular events (ACCLAIM-Lp(a))Written as Lepodisiran Sodium
- A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver FunctionCompletedPhase 1Eli Lilly and CompanyNCT06916078In hepatic impairmentWritten as Lepodisiran
- A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]CompletedPhase 2Eli Lilly and CompanyNCT05565742Dose finding in high Lp(a) (ALPACA)Written as LY3819469
- A Study of LY3819469 in Participants With Impaired and Normal Renal FunctionCompletedPhase 1Eli Lilly and CompanyNCT05841277In renal impairmentWritten as LY3819469
- A Study to Compare Two Formulations of LY3819469 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT05932446Two formulations comparedWritten as LY3819469
- A Study of LY3819469 in Healthy ParticipantsCompletedPhase 1Eli Lilly and CompanyNCT04914546First in human, in healthy participantsWritten as LY3819469
What changed recently
From the registry's own updates since Oct 18, 2026.
Newly registered1
- A Study of Lepodisiran (LY3819469) in Participants With High Lipoprotein(a)Nov 4, 2026NCT07914738
Codes
What other systems call lepodisiran · ClinicalTrials.gg INT018428
- UNII (FDA) X4BE7S8PN9LEPODISIRANOne source FDA
- NCI Thesaurus C203143LepodisiranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | X4BE7S8PN9 | LEPODISIRAN | One source FDA |
| NCI Thesaurus | C203143 | Lepodisiran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.